Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytori Therapeutics Inc    CYTX

CYTORI THERAPEUTICS INC (CYTX)
Mes dernières consult.
Most popular
Report
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Cytori Therapeutics Inc. (USA) : CORRECTING and REPLACING Cytori Enters $27 Million Term Loan with Oxford Finance Corporation and Silicon Valley Bank

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/01/2013 | 02:10pm CET

Third bullet point in release should read: The interest-only payment period may be extended by six months through January 2015 (sted The interest-only payment period may be extended by six months to January 2014)

The corrected release reads:

CYTORI ENTERS $27 MILLION TERM LOAN WITH OXFORD FINANCE CORPORATION AND SILICON VALLEY BANK

Cytori Therapeutics (NASDAQ: CYTX) entered into a four year, $27 million term loan with Oxford Finance Corporation and Silicon Valley Bank. The loan provides for an interest-only payment period of at least 12-months with the potential to be extended up to 18-months. Proceeds were used to prepay Cytori's existing loan with GE Capital, Oxford Finance Corporation, and Silicon Valley Bank. The loan was funded in full on June 28, 2013 and matures July 1, 2017.

Select terms of the loan include the following:

  • Fixed interest rate of 9.75% compared with 9.87% for the prior loan
  • Interest-only payments for 12-months followed by 36 equal monthly principal and interest payments
  • The interest-only payment period may be extended by six months through January 2015 should Cytori achieve $27 million in 12-month trailing revenues for the period ending June 30, 2014
  • Cytori will issue warrants to Oxford Finance Corporation and Silicon Valley Bank for the right to purchase an aggregate of 596,553 shares of the Company's common stock at an exercise price per share of $2.26 for seven years

"We worked closely with our lenders and were able to tailor a new loan that meets our specific needs," said Mark E. Saad, Chief Financial Officer, Cytori Therapeutics. "The loan provides an additional $8 million to help fund our ongoing operations, including clinical trial activities and reduces our near-term cash obligations by approximately $8 million to coincide with anticipated second half revenue growth."

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® System product family. www.cytori.com

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements including those regarding our expected second half revenue growth are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, risks related to our history of operating losses, the need for further financing and our ability to access the necessary additional capital for our business, inherent risk and uncertainty in the protection intellectual property rights, regulatory uncertainties, risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, as well as other risks and uncertainties described under the heading "Risk Factors" in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Cytori Therapeutics
Investors
Tom Baker, +1-858-875-5258
[email protected]
or
Media
Megan McCormick, +1-858-875-5279
[email protected]


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTORI THERAPEUTICS INC
03:01p Cytori Announces Expiration of Oversubscribed Rights Offering
11/23 CYTORI THERAPEUTICS : Maxim`s Target Price on Biotech Makes It More Than a Tenba..
11/21 CYTORI THERAPEUTICS : Reports Reduction in Fibrosis Parameters in Scar Study
11/20 Cytori Reports Reduction in Fibrosis Parameters in Scar Study
11/16 Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS
11/16 CYTORI THERAPEUTICS : Reminds Stockholders That Rights Offering Expires on Tuesd..
11/15 CYTORI THERAPEUTICS : Reminds Stockholders That Rights Offering Expires on Tuesd..
11/14 CYTORI THERAPEUTICS : Announces New U.S. Investigator Trial for Hip Osteonecrosi..
11/13 CYTORI THERAPEUTICS, INC. : Other Events (form 8-K)
11/13 Cytori Announces New U.S. Investigator Trial for Hip Osteonecrosis
More news
News from SeekingAlpha
2016 Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q1 2016 Results - Earnings Ca..
2016 Cytori Therapeutics EPS in-line, beats on revenue
2016 Cytori Cell Therapy an Orphan Drug in Europe for scleroderma-related hand dys..
2016 Notable earnings after Tuesday?s close
2016 Cytori's late-stage study of ECCS-50 in scleroderma 50% enrolled; study to co..
Financials ($)
Sales 2017 7,63 M
EBIT 2017 -19,3 M
Net income 2017 -22,8 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 1,77x
Capi. / Sales 2018 0,86x
Capitalization 13,5 M
Chart CYTORI THERAPEUTICS INC
Duration : Period :
Cytori Therapeutics Inc Technical Analysis Chart | CYTX | US23283K1051 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 2,08 $
Spread / Average Target 441%
EPS Revisions
Managers
NameTitle
Marc H. Hedrick President, Chief Executive Officer & Director
David M. Rickey Chairman
Tiago Girão CFO, Vice President & Head-Investor Relations
John K. Fraser Chief Scientist
Mark T. Marino Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CYTORI THERAPEUTICS INC-4.14%14
MEDTRONIC PLC15.60%111 537
BAXTER INTERNATIONAL44.43%34 891
C R BARD INC49.19%24 432
ZIMMER BIOMET HOLDINGS INC9.56%22 894
ALIGN TECHNOLOGY164.62%20 396